Are you Dr. Bhargava?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 51 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
Danafarber Cancer Institute
Boston, MA 02115Phone+1 617-632-6184Fax+1 617-632-5370
Summary
- Dr. Pankaj Bhargava, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts, California, and District of Columbia. He is affiliated with Dana-Farber Cancer Institute and Salem Hospital.
Education & Training
Georgetown University HospitalFellowship, Medical Oncology, 1995 - 1997
Maimonides Medical CenterResidency, Internal Medicine, 1992 - 1995
Delhi University College of Medical SciencesClass of 1991
Certifications & Licensure
DC State Medical License 1996 - Present
CA State Medical License 2007 - 2024
MA State Medical License 2000 - 2020
VA State Medical License 1996 - 2018- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Trial of PTK787/ZK 222584 Plus Paclitaxel Start of enrollment: 2006 Apr 26
- A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients Start of enrollment: 2007 Oct 01
Publications & Presentations
PubMed
- 6 citationsPhase II study of pemetrexed in patients with advanced neuroendocrine tumorsJennifer A. Chan, Andrew X. Zhu, Keith Stuart, Pankaj Bhargava, Craig C. Earle
Cancer Chemotherapy and Pharmacology. 2010-02-04 - 652 citationsGemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CA...Hedy L. Kindler, Donna Niedzwiecki, Donna Hollis, Susan Sutherland, Deborah Schrag
Journal of Clinical Oncology. 2010-08-01 - 25 citationsRandomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival.Manish A Shah, David Cunningham, Jean-Philippe Metges, Eric Van Cutsem, Zev Wainberg
Journal for Immunotherapy of Cancer. 2021-12-01
Press Mentions
MPM Capital Adds to Senior Team with the Appointment of Oncology Leader Pankaj Bhargava, MD as Executive PartnerApril 13th, 2021
Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1)May 13th, 2016- Dicerna Pharmaceuticals Appoints Dr. Pankaj Bhargava as Chief Medical OfficerApril 2nd, 2014
Professional Memberships
- Member
- Member
